Surface Oncology Incis A Clinical Stage Immuno Oncology Company Based In Cambridgemassachusettsfounded In 2014It Operates As A Subsidiary Of Coherus Biosciencesincthe Company Is Dedicated To Developing Innovative Antibody Therapies That Target The Tumor Microenvironment To Treat Various Types Of Cancer The Product Pipeline Includes Several Candidatessuch As Srf388Which Targets Interleukin 27 And Is In Phase Ii Trials For Multiple Cancerssrf617 Is A Monoclonal Antibody That Inhibits Cd39 And Is Being Studied For Gastricprostateand Pancreatic Cancersother Candidates Include Srf114Nzv930And Gsk4381562Each Targeting Different Mechanisms Involved In Cancer Progressionsurface Oncology Collaborates With Major Pharmaceutical Companies Like Novartis And Glaxosmithkline To Advance Its Therapiesaiming To Improve Outcomes For Cancer Patients Worldwide
